

5<sup>th</sup>

# World Bronchiectasis & NTM Conference




EMBARC

The European Bronchiectasis Registry

**FINAL PROGRAMME**

**Updated until 20/06/2022**



▶▶▶ **HYBRID FORMAT**

**PRAGUE**

**30 JUNE – 2 JULY 2022**

Organising Secretariat



Publi Créations

[www.world-bronchiectasis-conference.org](http://www.world-bronchiectasis-conference.org)



## **Welcome to the 5<sup>th</sup> World Bronchiectasis Conference!**

Dear Colleagues and Friends,

It is our great pleasure to welcome you in the 5<sup>th</sup> World Bronchiectasis & NTM Conference which is taking place in Prague from June 30<sup>th</sup> to July 2<sup>nd</sup>, 2022.

During this biennial appointment for the World Bronchiectasis & NTM Conference, that became a tradition, the small but very committed world community of scientists and experts in the field will **meet again to exchange and learn about the novelties in diagnosis, management and treatment of these complex pathologies** which are still often misdiagnosed and even more often overlooked.

While the knowledge in regard to the World Respiratory Medicine, Infectious Diseases and related Specialists is improving and while we advance in the understanding of the physiopathology, epidemiology and management outcomes, the **need to share knowledge and especially experience increase and the demand for further research emerges**.

**Within Bronchiectasis, a new definition and new research studies are providing** interesting insights about the inflammatory mechanism, while on NTM side, the publication of ATS/ERS/ESCMID/IDSA Guidelines in 2020 and their update expected in 2022 provide new tools to improve the management of patients.

Furthermore the need to have the patients managed by a multidisciplinary team to ensure the best outcome possible, creates the urge within the professionals to **develop or improve soft skills**, in order to be effectively able to communicate different points of view and collaborate on complex and sometimes very difficult cases where age, personal situation and comorbidities can change the approach of the pathology and the management of the patient. These skills will be the object of the training held during the **pre-congress post graduate courses and will be illustrated in the main programme by real – life cases**.

As always, the programme includes the **possibility for young researchers and clinicians to arise out of the international context** by presenting their valuable works during the **Rising Stars session**, while the most interesting abstracts presented by the scientific community will be included in the **oral presentation session** or in the **poster presentation sessions**.

Joining forces, exchanging clinical experiences, sharing data and tools, to **enforce the network of active experts in the field** are the main goals of the conference. We are pleased to meet you in person (or have you remotely connected)!

*The Organizing Committee*  
**Stefano Aliberti (Italy) Francesco Blasi (Italy), James D. Chalmers (UK)**



Organised by

**EMBARC**

The European Bronchiectasis Registry

Organising Secretariat



Publi Créations



## SPECIALTIES

The Conference Programme has been designed to fulfill the educational and updating needs of the professionals operating in the following specialties:

- Respiratory Medicine
- Internal Medicine
- Microbiology
- Physiotherapy
- Infectious Diseases & Virology
- Paediatrics
- Radiology
- Specialised Nursing

## VENUE



### VIENNA HOUSE ANDEL'S PRAGUE

**Address:** Stroupežnického 21, 15000 Prague

**Website:** <https://www.viennahouse.com/en/andels-prague/the-hotel/overview.html>

## WEBSITE



<https://www.world-bronchiectasis-conference.org/>

## ORGANISER



**EMBARC**

The European Bronchiectasis Registry



**EMBARC**

The European Bronchiectasis Registry





## ORGANISING COMMITTEE



**Stefano Aliberti**  
(Italy)



**Francesco Blasi**  
(Italy)



**James D. Chalmers**  
(UK)

## SCIENTIFIC COMMITTEE



**Timothy Aksamit**  
(USA)



**Kristian Brat**  
(Czech Republic)



**Raja Dhar**  
(India)



**Stuart Elborn**  
(UK)



**Pieter C. Goeminne**  
(Belgium)



**Wei-Jie Guan**  
(China)



**Charles S. Haworth**  
(UK)



**Michael Loebinger**  
(UK)



**Lucy Morgan**  
(Australia)



**Michal Shteinberg**  
(Israel)



**Antoni Torres**  
(Spain)



**Montserrat Vendrell**  
(Spain)



**Tobias Welte**  
(Germany)



## TOPICS

Airways Inflammation

Artificial Intelligence

### **BRONCHIECTASIS**

Covid-19

Cystic Fibrosis

Epidemiology

Etiology

Exacerbations

Imaging

Immunology

Inhaled Antibiotics

International Guidelines


Microbiome

### **NTM**

Paediatrics

PCD / Cilia

Treatments





## FACULTY

Timothy Aksamit (USA)

Zina Alfahl (UK)

Stefano Aliberti (Italy)

Andrea Aliverti (Italy)

Marta Almagro (Spain)

Claire Andrejak (France)

Rodrigo Athanazio (Brazil)

Francesco Blasi (Italy)

Mathieu Bottier (France)

Judy Bradley (UK)

Kristian Brat (Czech Republic)

Erin Cant (UK)

James D. Chalmers (UK)

Anne Chang (Australia)

Yoon Kyung (Rachel) Chang (Australia)

Sanjay Chotirmall (Singapore)

Mario Clerici (Italy)

M. Leigh Anne Daniels (USA)

Antony De Soyza (UK)

Raja Dhar (India)

Katerina Dimakou (Greece)

Stuart Elborn (UK)

Charles Feldman (South Africa)

Ilaria Ferrarotti (Italy)

Andres Floto (UK)

Pieter C. Goeminne (Belgium)

Andrea Gori (Italy)

Wei-Jie Guan (China)

Shirley Harwood (UK)

Charles S. Haworth (UK)

Adam Hill (UK)

Vladimir Koblizek (Czech Republic)

Zichuan Li (China)

Michael Loebinger (UK)

Jane Lucas (UK)

Paul McCallion (UK)

Pamela J. McShane (USA)

Mark Metersky (USA)

Lucy Morgan (Australia)

Jayanth K. Narayana (Singapore)

Anne O'Donnell (USA)

Kenneth Olivier (USA)

Petr Pohunek (Czech Republic)

Jelmer Raaijmakers (Netherlands)

Mark Schoenfisch (USA)

Amelia Shoemark (UK)

Michal Shteinberg (Israel)

Oriol Sibila (Spain)

Libuše Smolíková (Czech Republic)

Ivan Solovic (Slovakia)

Gregory Tino (USA)

Antoni Torres (Spain)

Jakko van Ingen (Netherlands)

Montserrat Vendrell (Spain)

Tobias Welte (Germany)

Kevin Winthrop (USA)



## SCIENTIFIC PROGRAMME | Thursday June 30<sup>th</sup>, 2022

**14.00 - 17.00**

### **ROUND TABLES**

The Faculty and participants will discuss of real-life cases presented by participants. Each participant can attend two different round tables during the period.

**Pre-registration is mandatory**, places are limited to 30 per round tables  
- first come first served.

14.00 - 15.30

### **FIRST ROUND | Real-Clinical Cases Discussion**

**Room A:** Difficult to treat pathogens

*Faculty:* Charles S. Haworth (UK)

**Room B:** Difficult to treat NTM

*Faculty:* Timothy Aksamit (USA), Jakko van Ingen (Netherlands)

**Room C:** Supported Round Table on Mucus Clearance (see details page 20)

**Room D:** Management of Exacerbations in bronchiectasis

*Faculty:* Adam Hill (UK), Pamela J. McShane (USA)

15.30 - 17.00

### **SECOND ROUND | Real-Clinical Cases Discussion**

**Room A:** Difficult to treat pathogens

*Faculty:* Charles S. Haworth (UK)

**Room B:** Difficult to treat NTM

*Faculty:* Timothy Aksamit (USA), Jakko van Ingen (Netherlands)

**Room C:** Supported Round Table on Mucus Clearance (see details page 20)

**Room D:** Management of Exacerbations in bronchiectasis

*Faculty:* Adam Hill (UK), Pamela J. McShane (USA)

17.00 - 17.30

### **WELCOME COFFEE**



## SCIENTIFIC PROGRAMME | Thursday June 30<sup>th</sup>, 2022

### 17.30 - 17.45 OPENING ADDRESS

17.30 - 17.40 **Opening Addresses**  
*Stefano Aliberti (Italy), Francesco Blasi (Italy), James D. Chalmers (UK)*

17.40 - 17.45 **World Bronchiectasis Day**  
*Timothy Aksamit (USA)*

### 17.45 - 18.30 OPENING LECTURE

***Chairs:*** Francesco Blasi (Italy), James D. Chalmers (UK)

17.45 - 18.15 **Moving forward in the Post Covid Era**  
*Stuart Elborn (UK)*

18.15 - 18.30 **Discussion**

### 18.30 - 19.30 ROUND TABLE

18.30 - 19.30 **Bronchiectasis Management Worldwide:  
what's common, what's different, what can we learn?**

***Moderator:*** Stefano Aliberti (Italy)

***Discussants:*** Rodrigo Athanazio (Brazil), Raja Dhar (India), Charles Feldman (South Africa), Lucy Morgan (Australia), Anne O'Donnell (USA), Michal Shteinberg (Israel), Oriol Sibila (Spain)

***Final Sum-up by:*** Stefano Aliberti (Italy) & James D. Chalmers (UK)

### 19.30 - 20.00 LECTURE

***Chairs:*** Stefano Aliberti (Italy), Kristian Brat (Czech Republic)

19.30 - 19.50 **NTM in Central Europe: state of the art and challenges**  
*Ivan Solovic (Slovakia)*

19.50 - 20.00 **Discussion**

20.00 **WELCOME SESSION**





## SCIENTIFIC PROGRAMME | Friday July 1<sup>st</sup>, 2022

### 08.30 - 09.10 KEYNOTE LECTURE 1

*Chair: Timothy Aksamit (USA)*

08.30 - 09.00 **Impact of climate change on respiratory infections**  
*Andrea Gori (Italy)*

09.00 - 09.10 **Discussion**

### 09.10 - 10.00 S.1 RISING STARS SESSION WITH AWARD

*Chairs: Stefano Aliberti (Italy), Francesco Blasi (Italy), James D. Chalmers (UK)*

09.10 - 09.25 **Sputum microbiome and clinical outcome measures in bronchiectasis: Data from the BRONCH UK Study**  
*Zina Alfahl (UK)*

09.25 - 09.30 **Discussion**

09.30 - 09.45 **Rifampicin has no clear role in the standard regimen for M. avium complex lung disease - A hollow-fibre study with genome-wide transcriptional analysis**  
*Jelmer Raaijmakers (Netherlands)*

09.45 - 09.50 **Discussion**

09.50 - 10.00 **Awards Ceremony to the Rising Stars**  
*Delivery of David Serisier Award for Bronchiectasis - presented by Lucy Morgan (Australia)*

*Delivery of Won-Jung Koh Award for NTM - presented by Timothy Aksamit (USA)*

### 10.00 - 10.30 KEYNOTE LECTURE 2

*Chair: Lucy Morgan (Australia)*

10.00 - 10.20 **TB, traction and tricky bronchiectasis**  
*Raja Dhar (India)*

10.20 - 10.30 **Discussion**



## SCIENTIFIC PROGRAMME | Friday July 1<sup>st</sup>, 2022

10.30 - 11.00 COFFEE BREAK

### 11.00 - 12.40 S.2 MANAGEMENT OF BRONCHIECTASIS COMORBIDITIES

*Chairs: Anne O'Donnell (USA), Tobias Welte (Germany)*

11.00 - 11.20 **Bronchiectasis and COPD overlap management- reality or fiction**  
- data from Czech Multicenter Research Database of COPD  
*Vladimir Koblizek (Czech Republic)*

11.20 - 11.40 **Emerging understandings on the impact of rare SERPINA1 mutations and their clinical manifestations in rare lung diseases**  
*Ilaria Ferrarotti (Italy)*

11.40 - 12.00 **Severe Asthma: T2 high and T2 low**  
*Stefano Aliberti (Italy)*

12.00 - 12.20 **Autoimmune diseases: from RA to IBD**  
*Antony De Soyza (UK)*

12.20 - 12.40 **Discussion**  
*Discussant: Kristian Brat (Czech Republic)*

12.40 - 14.10 **LUNCH BREAK & STROLLING POSTER SESSIONS** (see details page 14-16)

### 14.10 - 15.30 S.3 BRONCHIECTASIS AND CYSTIC FIBROSIS: SOMETHING MORE THAN PSEUDOMONAS

*Chairs: Michael Loebinger (UK), Antoni Torres (Spain)*

14.10 - 14.30 **Spectrum of fungal diseases**  
*Sanjay Chotirmall (Singapore)*

14.30 - 14.50 **Viral infections**  
*Wei-Jie Guan (China)*

14.50 - 15.10 **NTM infections**  
*Claire Andrejak (France)*

15.10 - 15.30 **Discussion**



## SCIENTIFIC PROGRAMME | Friday July 1<sup>st</sup>, 2022

15.30 - 16.00 COFFEE BREAK

### 16.00 - 17.00 ORAL PRESENTATIONS

*Chairs:* Michal Shteinberg (Israel), Gregory Tino (USA)

Each presentation will be 10' long followed by a 5' discussion time

16.00 - 16.15 **Characterisation of Ciliary Function in a European Cohort of Bronchiectasis Patients: The EMBARC-BRIDGE cilia study**  
*Mathieu Bottier (France)*

16.15 - 16.30 **A Th2 endotype in bronchiectasis associated with impaired cilia function**  
*Erin Cant (UK)*

16.30 - 16.45 **Impact of ciprofloxacin treatment on Pseudomonas aeruginosa phenotypes in vitro**  
*Zichuan Li (China)*

16.45 - 17.00 **Preclinical evaluation of a nitric oxide-releasing prodrug as a treatment for chronic Mycobacterium abscessus infections**  
*Mark Schoenfisch (USA)*

17.00 - 18.00 SPONSORED LECTURE (see details page 20)

### 18.00 - 18.40 KEYNOTE LECTURE 3

*Chair:* Michael Loebinger (UK)

18.00 - 18.30 **Artificial intelligence in the radiological diagnosis of bronchiectasis**  
*Andrea Aliverti (Italy)*

18.30 - 18.40 Discussion



## SCIENTIFIC PROGRAMME | Saturday July 2<sup>nd</sup>, 2022

### 08.30 - 09.00 PATIENTS VOICES

*Chairs:* Katerina Dimakou (Greece), Montserrat Vendrell (Spain)

#### 08.30 - 08.45 How to live with Bronchiectasis

*Marta Almagro (Spain)*

#### 08.45 - 09.00 How to live with NTM

*Shirley Harwood (UK)*

### 09.00 - 09.55 S.4 RESPIRATORY IMMUNOLOGY

*Chairs:* Mario Clerici (Italy), Pamela J. McShane (USA)

#### 09.00 - 09.20 Innate and adaptive immunity in bronchiectasis and NTM

*Kenneth Olivier (USA)*

#### 09.20 - 09.40 Spectrum of patients with immunodeficiencies

*Michal Shteinberg (Israel)*

#### 09.40 - 09.55 Discussion

### 09.55 - 10.30 KEYNOTE LECTURE 4

*Chair:* Lucy Morgan (Australia)

#### 09.55 - 10.20 Bronchiectasis in children: what can we learn as "adultologists"

*Anne Chang (Australia)*

#### 10.20 - 10.30 Discussion

### 10.30 - 11.00 COFFEE BREAK

### 11.00 - 11.30 KEYNOTE LECTURE 5

*Chair:* Mark Metersky (USA)

#### 11.00 - 11.20 Inhaled phage therapy for treatment of respiratory infections

*Yoon Kyung (Rachel) Chang (Australia)*

#### 11.20 - 11.30 Discussion





## SCIENTIFIC PROGRAMME | Saturday July 2<sup>nd</sup>, 2022

**11.30 - 12.30**

### **S.5 PCD / CILIA**

*Chairs:* M. Leigh Anne Daniels (USA), Jane Lucas (UK)

11.30 - 11.50

#### **What does ciliopathy mean in bronchiectasis**

*Amelia Shoemark (UK)*

11.50 - 12.10

#### **PCD in childhood - is early diagnosis a link to improved prognosis and quality of life?**

*Petr Pohunek (Czech Republic)*

12.10 - 12.30

#### **Discussion**

**12.30 - 13.10**

### **KEYNOTE LECTURE 6**

*Chair:* Pieter C. Goeminne (Belgium)

12.30 - 13.00

#### **Gut-lung microbiome in bronchiectasis**

*Jayanth K. Narayana (Singapore)*

13.00 - 13.10

#### **Discussion**

**13.10 - 13.25**

### **EMBARC SESSION**

13.10 - 13.25

#### **Embarc 3**

*James D. Chalmers (UK)*

13.25 - 14.50

#### **LUNCH BREAK & STROLLING POSTER SESSIONS** (see details page 17-19)

**14.50 - 15.50**

### **S.6 IDIOPATHIC NO – MORE**

*Chairs:* Gregory Tino (USA), Kevin Winthrop (USA)

14.50 - 15.10

#### **New insights in pathophysiology of bronchiectasis**

*Pamela J. McShane (USA)*

15.10 - 15.30

#### **Genomics of Bronchiectasis: a new era**

*Andres Floto (UK)*

15.30 - 15.50

#### **Discussion**

15.50 - 16.10

### **CLOSING REMARKS**

*Stefano Aliberti (Italy), Francesco Blasi (Italy), James D. Chalmers (UK)*

**Full hybrid format:** All the sessions will be realised in presence. Eventually, with the remote connection of some Chairs or Speakers. All the sessions will be broadcasted live on the Virtual Platform (accessible from the congress website) for all the participants who will be connected remotely.



## STROLLING POSTER SESSIONS | Friday July 1<sup>st</sup>, 2022

12.40 - 13.40

**STROLLING POSTER SESSION 10A - IN PRESENCE (FOYER)**

*Chairs:* Timothy Aksamit (USA), Raja Dhar (India), Antoni Torres (Spain)

BRONCHIECTASIS	10A.1	Exacerbation rates before and during the COVID-19 pandemic in non-cystic fibrosis bronchiectasis: a retrospective claims study <i>Astrand Annika (Sweden)</i>
	10A.2	Study design of a Phase II, randomized, double-blind, placebo-controlled trial of a novel cathepsin C inhibitor BI 1291583 in patients with bronchiectasis <i>Chalmers James D. (UK)</i>
	10A.3	Design of the 52-week Phase 3 MAHALE Study of Benralizumab in Patients with Non-Cystic Fibrosis Bronchiectasis <i>Chalmers James D. (UK)</i>
	10A.4	Brensocatib for the Treatment of Non-Cystic Fibrosis Bronchiectasis (NCFBE): Number Needed to Treat (NNT) and Number Needed to Harm (NNH) <i>Chalmers James D. (UK)</i>
	10A.5	Patient representative engagement and collaboration in the study design of Airleaf™: A multinational Phase 2 trial of a novel cathepsin C inhibitor for the treatment of bronchiectasis <i>Chalmers James D. (UK)</i>
	10A.6	The Association between Anxiety, Depression, Physical Disease Parameters, and Health-Related Quality of Life in the BronchUK national Bronchiectasis cohort <i>De Soyza Anthony (UK)</i>
	10A.7	Bronchiectasis and asthma coexistence; clinical, radiological and bacteriological characteristics of a group of 66 cases <i>Digalaki Antonia (Greece)</i>
	10A.8	Microbiome characterization in patients with bronchiectasis and its association with severity and bronchial inflammation. Bronchi-Omics Project <i>Gonçalves dos Santos Carvalho Filipe (Spain)</i>
	10A.9	The need for a remote (virtual) exercise and lifestyle education program in Bronchiectasis and NTM <i>Horvat Emily (Canada)</i>
	10A.10	Phase I characterization of the novel cathepsin C inhibitor BI 1291583 <i>Kögler Harald (Germany)</i>
	10A.11	The Association Between Bronchiectasis and Chronic Obstructive Pulmonary Disease: Data From The European Bronchiectasis Registry (EMBARC) <i>Traversi Letizia (Spain)</i>



## STROLLING POSTER SESSIONS | Friday July 1<sup>st</sup>, 2022

**12.40 - 13.40 STROLLING POSTER SESSION 10B - IN PRESENCE (FOYER)**

*Chairs: Stefano Aliberti (Italy), Tobias Welte (Germany)*

<b>TREATMENTS</b>	<b>10B.0</b>	Effect of omalizumab on lung function, glucocorticoid use and exacerbations in patients with allergic bronchopulmonary aspergillosis: a systematic review and meta-analysis <i>Elborn Stuart (UK)</i>
<b>EPIDEMIOLOGY</b>	<b>10B.1</b>	Prevalence and Causes of Bronchiectasis among high altitude people, HRCT Chest study <i>Pal Anusmriti (Nepal)</i>
<b>IMAGING</b>	<b>10B.2</b>	Radiological features and disease severity in patients with bronchiectasis: an observational study <i>Abo-Leyah Hani (UK)</i>
<b>NTM</b>	<b>10B.3</b>	Trends in non-Tuberculous mycobacteria isolation in Northern Israel <i>Cohen Raya (Israel)</i>
	<b>10B.4</b>	Development of a brief respiratory symptoms scale for M. avium complex pulmonary disease <i>Henkle Emily (USA)</i>
	<b>10B.5</b>	Nutritional assessment in non-tuberculous mycobacteria pulmonary disease (nutriNTM): rationale and study protocol <i>Landoni Valentina (Italy)</i>
	<b>10B.6</b>	Testing at-risk patients for NTM-PD in current clinical practice: results of an international survey <i>Loebinger Michael (UK)</i>
	<b>10B.7</b>	A systematic literature review and meta-analysis of patient risk factors for non-tuberculous mycobacterial pulmonary disease (NTM-PD) <i>Loebinger Michael (UK)</i>
	<b>10B.8</b>	Reduction in Hospitalizations After Initiation of Amikacin Liposome Inhalation Suspension (ALIS): A Retrospective Cohort Study of Patients in Real-World Settings <i>Obradovic Marko (Slovenia)</i>
	<b>10B.9</b>	Epidemiology of Non-Tuberculous Mycobacteria in Bologna, Northern Italy, in the last ten years (2012-2021) <i>Pozzi Anna (Italy)</i>
	<b>10B.10</b>	Clofazimine is a safe and effective replacement for rifampicin in Mycobacterium avium complex pulmonary disease treatment – primary outcomes of the PERC trial <i>Zweijpfenning Sanne M.H. (Netherlands)</i>



## STROLLING POSTER SESSIONS | Friday July 1<sup>st</sup>, 2022

**12.40 - 13.40 STROLLING POSTER SESSION 1V - VIRTUAL (PLENARY ROOM)**

**Chairs:** Wei-Jie Guan (China), Michal Shteinberg (Israel)

<b>BRONCHIECTASIS</b>	<b>1V.1</b>	Imaging analysis of sarcopenia in a cohort of stable patients with bronchiectasis <i>Alvarado Miranda Mariela Nieves (Spain)</i>
	<b>1V.2</b>	Viral load analysis of spirometry filters in patients with chronic respiratory disease whilst asymptomatic of acute viral respiratory tract infection <i>Goldsmith James (Australia)</i>
	<b>1V.3</b>	The relationship between airway Interleukin-1 beta, microbial dysbiosis and mucus hyperconcentration in bronchiectasis: The EMBARC-BRIDGE study <i>Perea Lidia (UK)</i>
	<b>1V.4</b>	Diagnostic value of the Biofire® Filmarray Pneumonia panel compared to conventional sputum culture in patients with an exacerbation of bronchiectasis <i>Rovira-Ribalta Nona (Spain)</i>
	<b>1V.5</b>	A questionnaire to assess adherence to respiratory physiotherapy in patients with bronchiectasis: a preliminary study <i>Santambrogio Martina (Italy)</i>
	<b>1V.6</b>	Multicenter, Pragmatic, Randomized, Controlled Trial to Assess the Efficacy and Safety of Nocturnal Humidification Therapy in Patients with Bronchiectasis: the AIRVO-BX Study <i>Santambrogio Martina (Italy)</i>
	<b>1V.7</b>	Bridging the Gap: A Novel Symptom Diary for Non-Cystic Fibrosis Bronchiectasis (NCFB) Exacerbations <i>Shih Vivian H. (USA)</i>
<b>ETIOLOGY</b>	<b>1V.8</b>	Morphological aspects of pulmonary nocardiosis <i>Gori Leonardo (Italy)</i>
<b>TREATMENTS</b>	<b>1V.9</b>	A laboratory assessment of nebulized medication delivery through different Oscillating Positive Expiratory Pressure (OPEP) devices – not all devices are the same <i>Suggett Jason (Canada)</i>
	<b>1V.10</b>	Respiratory physiotherapy in private practice: an audit of clinical practice and quality of life outcomes in patients with bronchiectasis <i>Taylor Mitchell (Australia)</i>





## STROLLING POSTER SESSIONS | Saturday July 2<sup>nd</sup>, 2022

13.25 - 14.25

### STROLLING POSTER SESSION 20A - IN PRESENCE (FOYER)

**Chairs:** Kristian Brat (Czech Republic), James D. Chalmers (UK), Montserrat Vendrell (Spain)

BRONCHIECTASIS	20A.1	Effect of glycaemia on lung function in people with bronchiectasis- a retrospective analysis <i>Cohen Raya (Israel)</i>
	20A.2	In vitro and in vivo characterization of the novel cathepsin C inhibitor BI 1291583 <i>Kreideweiss Stefan (Germany)</i>
	20A.3	Investigation of exoU in Pseudomonas aeruginosa respiratory infections from people with bronchiectasis <i>Li Zichuan (China)</i>
	20A.4	Prevalence of Breathing Pattern Disorder in a Physiotherapy Bronchiectasis Outpatients Clinic <i>McCallion Paul (UK)</i>
	20A.5	Bronchiectasis and other imaging changes on thoracic computed tomography (CT) in adult cystic fibrosis (CF) patients in North Macedonia <i>Momchilovikj Sonja (Macedonia - North)</i>
	20A.6	Eosinophil Peroxidase is a Proteomic Marker of Bronchiectasis Disease Severity <i>Pollock Jennifer (UK)</i>
	20A.7	Aetiology and Clinical Characteristics of Non-CF Bronchiectasis Cohort in a Middle Eastern Population <i>Shafiq Irfan (United Arab Emirates)</i>
	20A.8	Rates of Pseudomonas aeruginosa in bronchiectasis patients on long-term ventilation <i>Sobala Ruth (UK)</i>
	20A.9	Multimorbidity in bronchiectasis: a systematic scoping review <i>Sobala Ruth (UK)</i>
	20A.10	Prevalence of T2-High endotype in adults with bronchiectasis in Ukraine <i>Suska Kseniia (Ukraine)</i>
	20A.11	Prevalence of eosinophilia in two cohorts of bronchiectasis patients with and without asthma <i>van der Veer Tjeerd (Netherlands)</i>



## STROLLING POSTER SESSIONS | Saturday July 2<sup>nd</sup>, 2022

**13.25 - 14.25 STROLLING POSTER SESSION 2OB - IN PRESENCE (FOYER)**

*Chairs: Francesco Blasi (Italy), Charles S. Haworth (UK)*

<b>AIRWAYS INFLAMMATION</b>	<b>2OB.1</b>	<b>Sputum Biomarkers and Exacerbations in People with CF</b> <i>Liou Theodore G. (USA)</i>
<b>EXACERBATIONS</b>	<b>2OB.2</b>	<b>Assessing Severity of Chronic Obstructive lung disease (COPD) Using CAT score among high altitude residents of Nepal</b> <i>Yadav Manoj Kumar (Nepal)</i>
<b>PCD / CILIA</b>	<b>2OB.3</b>	<b>Characteristics of adult PCD patients: a single-center experience</b> <i>Kosti Chrysavgi (Greece)</i>
	<b>2OB.4</b>	<b>Genome sequencing reveals underdiagnosis of primary ciliary dyskinesia in bronchiectasis</b> <i>Shoemark Amelia (UK)</i>
	<b>2OB.5</b>	<b>Development and first results of the BEAT-PCD international Primary Ciliary Dyskinesia gene variant database: CiliaVar</b> <i>Shoemark Amelia (UK)</i>
<b>TREATMENTS</b>	<b>2OB.6</b>	<b>QTc interval prolongation in NTM disease treatment with Azithromycin</b> <i>Bindo Francesco (Italy)</i>
	<b>2OB.8</b>	<b>Feasibility of implementing innovative airway clearance technology at home by telecare in patients with non-cystic fibrosis bronchiectasis</b> <i>Morin Laurent (France)</i>



## STROLLING POSTER SESSIONS | Saturday July 2<sup>nd</sup>, 2022

13.25 - 14.25

### STROLLING POSTER SESSION 2V - VIRTUAL (PLENARY ROOM)

**Chairs:** Pieter C. Goeminne (Belgium), Michael Loebinger (UK), Lucy Morgan (Australia)

INHALED ANTIBIOTICS	2V.1	Assessing quantitative PCR method in determining <i>P. aeruginosa</i> bacterial load: Correlation with clinical endpoints in bronchiectasis patients (iBEST study) <i>Alkhatib Aya (UK)</i>
	2V.2	Phage Cocktail Powders for <i>Pseudomonas aeruginosa</i> Respiratory Infections <i>Li Mengyu (Australia)</i>
	2V.3	Phenotypic characterisation of <i>Pseudomonas aeruginosa</i> isolates from people with bronchiectasis following experimental induction of tobramycin resistance <i>McCleave Ross (UK)</i>
MICROBIOME	2V.4	Rapid molecular detection of bacterial infection and antimicrobial resistance in bronchiectasis <i>Richardson Hollian (UK)</i>
NTM	2V.5	<i>Mycobacterium abscessus</i> infection in a patient with second motor neuron disease and chronic respiratory failure <i>Esposito Danilo (Italy)</i>
	2V.6	Characteristics of patients with bronchiectasis associated with risk for nontuberculous mycobacterial infection <i>Izhakian Shimon (Israel)</i>
	2V.7	NTM : The Biggest TB Mimic in an endemic country like India <i>Toshniwal Bharat (India)</i>
PCD / CILIA	2V.8	Describing the Ear, Nose, and Throat symptom burden in a cohort of Australian patients with Primary Ciliary Dyskinesia <i>Ryan Peter (Australia)</i>
	2V.9	Correlation of genotype, phenotype and ciliary ultrastructure in adults with bronchiectasis, suspected primary ciliary dyskinesia (PCD) and inconclusive genetics <i>Staar Ben (Germany)</i>



## SUPPORTED SESSIONS

**DISCLAIMER:** THE FOLLOWING SESSIONS ARE ORGANIZED BY INDUSTRIES, YOU CANNOT CLAIM CME CREDITS FOR ATTENDING THESE SESSIONS.

### Thursday June 30<sup>th</sup>, 2022

#### FIRST ROUND | Real-Clinical Cases Discussion

Supported by Physio-Assist

14.00 - 15.30

**Room C: Nonpharmacological strategies to mucus clearance**

*Faculty:* Judy Bradley (UK), Paul McCallion (UK), Michal Shteinberg (Israel),  
Libuše Smolíková (Czech Republic)

#### SECOND ROUND | Real-Clinical Cases Discussion

Supported by Physio-Assist

15.30 - 17.00

**Room C: Nonpharmacological strategies to mucus clearance**

*Faculty:* Judy Bradley (UK), Paul McCallion (UK), Michal Shteinberg (Israel),  
Libuše Smolíková (Czech Republic)

### Friday July 1<sup>st</sup>, 2022

#### SPONSORED LECTURE

Supported by Insméd

17.00 - 17.45

**The role of neutrophilic inflammation in bronchiectasis**

*James D. Chalmers (UK)*

17.45 - 18.00

**Discussion**



Organising Secretariat



[www.world-bronchiectasis-conference.org](http://www.world-bronchiectasis-conference.org)

5<sup>th</sup>

## World Bronchiectasis & NTM Conference

▶▶▶ HYBRID FORMAT

**PRAGUE, 30 JUNE – 2 JULY 2022**

*The meeting content is made available  
for remotely connected participants by an  
independent educational grant of  
Boehringer Ingelheim*



# Boehringer Ingelheim

Organising Secretariat



Organised by



EMBARC

The European Bronchiectasis Registry



## GENERAL INFORMATION

### ORGANISING SECRETARIAT

For any kind of information related to the Conference please contact Publi Créations:

#### PUBLI CREATIONS S.A.M.

Address: 74 Boulevard d'Italie, 98000 MONACO

Phone Number: +377 97 97 35 55

Site: [www.publiccreations.com](http://www.publiccreations.com)

Email: [wbc@publiccreations.com](mailto:wbc@publiccreations.com)

### SECRETARIAT DESK

The secretariat desk will open on June 30<sup>th</sup> from 11.00 am and will be open as follows:

- **June 30<sup>th</sup>, 2022:** 11.00 am - 09.00 pm (*end of the welcome session*)
- **July 1<sup>st</sup>, 2022:** 08.00 am - 07.30 pm
- **July 2<sup>nd</sup>, 2022:** 08.00 am - 04.10 pm (*end of the Conference*)

### EXHIBITION

The set up and dismantling of the exhibition area will be accessible only for sponsors with an exhibition booth.

- **Set up:** June 30<sup>th</sup>, 2022 from 08.00 am to 01.00 pm
- **Dismantling:** July 2<sup>nd</sup>, 2022 from 04.00 pm to 06.00 pm

### ADMISSION

The participant's name badge will be provided by the Organizing Secretariat via email. All participants are requested to print it and wear the badge throughout the conference. Only badge holders will be admitted to the appropriate sessions, exhibition and poster area as well as social events.

### HEALTHCARE MEASURES

Please check on the congress website [www.world-bronchiectasis-conference.org](http://www.world-bronchiectasis-conference.org) the updated healthcare measures to access the country. It is recommended the use of FFP2 masks while in the congress and in the exhibition area. Gel and masks will be available in the congress and in the

coffee break area.

A COVID center is right next to the conference venue, for any information please see the following website: [covid.altoa.cz/en/pcr-test/self-payer](https://covid.altoa.cz/en/pcr-test/self-payer)

### PRESENCE CONTROL

Effective attendance is checked through badge scanning when entering and coming out of the plenary room. A minimum of 6 hours of effective attendance is required to get the certificate of attendance.

### Wi-Fi AT THE CONGRESS VENUE

Free Wi-Fi will be available for all congress participants at the congress venue.

- **Wi-Fi network:** AND-CONF • **Password:** Vienna.2020

### CONGRESS APP / VIRTUAL PLATFORM

We invite virtual participants to follow the congress online through the congress website [www.world-bronchiectasis-conference.org](http://www.world-bronchiectasis-conference.org).

By clicking on "Virtual Platform" from the Home page and by inserting the credentials you have created while registering (and you may find in the confirmation letter received few days before the congress starting date) you can follow the conference live, ask questions, consult the programme and the participant list.

Onsite participants may enter the virtual platform from their mobile to access easily to the congress programme and participant list.

*The meeting content is made available for remotely connected participants by an independent educational grant of Boehringer Ingelheim.*



The virtual platform of the event will be available starting from June 29<sup>th</sup>, 2022.



## GENERAL INFORMATION

### CERTIFICATE OF ATTENDANCE

The certificate of attendance will be downloadable from the website [www.world-bronchiectasis-conference.org](http://www.world-bronchiectasis-conference.org) using your personal credentials sent by e-mail, starting from July 6<sup>th</sup>, 2022.

**Important note:** Certificate of attendance will be delivered only to registered participants who attended at least 6 hours of congress sessions.

**For Sponsored Groups:** Please note that in order to send the certificate of attendance to each participant, we will need the personal email.

### EUROPEAN ACCREDITATION

The 5<sup>th</sup> World Bronchiectasis & NTM Conference is granted with 17 CME credits (ECMECs®) by the **European Accreditation Council for Continuing Medical Education (EACCME®)** and 17 European CME credits by the **European Board for Accreditation in Pneumology (EBAP)**.

The Credits Certificate is delivered to those having attended the Conference (at least 6h) and having filled the online Scientific Questionnaire.

To download your certificate please log in to the [www.world-bronchiectasis-conference.org](http://www.world-bronchiectasis-conference.org) using the personal login credentials sent by e-mail, starting from July 6<sup>th</sup>, 2022.

CME Credits certificates will be downloadable up to July 24<sup>th</sup>, 2022. After this date, in order to comply with the reporting deadline of UEMS, the CME Credits will no longer be downloadable.

**For Sponsored Groups:** Please note that in order to provide the CME certificate to each participant, we will need their personal email address.

### INSURANCE

The Congress Organizer cannot accept liability for last minute cancellations, personal injuries sustained, or for loss or damage to property belonging to Congress participants, either during or as a result of the Congress. Registration does not include insurance.

It is strongly recommended to subscribe an insurance policy of your choice as you register for the Congress and book your travel.

### LANGUAGE

The official language of the Congress is English. No simultaneous translation will be provided.

### ACCESS TO RECORDED SESSIONS AFTER THE LIVE EVENT

Authorized recorded sessions and lectures will be available for all registered participants on the congress website [www.world-bronchiectasis-conference.org](http://www.world-bronchiectasis-conference.org) from July 7<sup>th</sup> to December 31<sup>st</sup>, 2022. To access them click on the "virtual platform" button and enter your personal credentials.



# 5<sup>th</sup> World Bronchiectasis & NTM Conference


**PRAGUE**  
30 JUNE – 2 JULY 2022

HYBRID FORMAT


[www.world-bronchiectasis-conference.org](http://www.world-bronchiectasis-conference.org)



## ENDORSEMENTS



Slovenská pneumologická a fyziologická spoločnosť



MEDIA PARTNER:







## ACKNOWLEDGEMENTS

The Organizing and Scientific Committee of the  
**5<sup>th</sup> World Bronchiectasis & NTM Conference**  
would like to express their gratitude to:

### MAJOR PARTNER



### PARTNERS



### SUPPORTERS



### GRANT



# INTERNATIONAL WORKSHOP ON LUNG HEALTH

Respiratory Diseases and  
*Immune response*



NICE, JANUARY 19-21 2023



## Organizing Committee

G. WALTER CANONICA, Italy



TOBIAS WELTE, Germany



FRANCESCO BLASI, Italy



STEFANO CENTANNI, Italy



JOHANN CHRISTIAN VIRCHOW, Germany

## MAIN TOPICS

- ◊ Asthma
- ◊ COPD
- ◊ Rare diseases
- ◊ Respiratory Infections

## ABSTRACT CALL & POSTER PRIZES

Don't miss the opportunity to **present your original scientific work** during the IWLH Strolling Poster Session and compete for the **Poster Awards**.

Visit [www.lung-health.org/2023](http://www.lung-health.org/2023) and submit your abstract within **October 24<sup>th</sup>, 2022**

## Scientific Committee

JAMES D. CHALMERS, UK



DAIANA STOLZ, Germany



STEFANO ALIBERTI, Italy



ENRICO M. HEFFLER, Italy



FABIANO DI MARCO, Italy

## SUPPORTING YOUNG GENERATION



### FUHeL MENTORING PROGRAMME

Congresses and workshops are the most important mean of continuing medical education after University. The **FUHeL Programme** offers an opportunity of a personalised mentoring.

**Join the FUHEL Community!**  
Candidate yourself on the **IWLH Web site**



### RISING STARS

Two young researchers / clinicians, selected by a strict process, will have the opportunity to be part of the Faculty. **Take the chance: visit the Workshop web site for more information**



### LUNGonAIR CONTEST

Do you want to **challenge your colleagues from all over the World in the first worldwide contest in Respiratory Medicine?**

Are you a young researcher or clinician **under 42?**  
Start working on your team construction!  
From July 2022 the application process will be opened on the IWLH Web-site! Don't miss the challenge! Stay tuned.

**Don't miss the IWLH Young Opportunities. Visit the web site and submit your candidacy within **October 24<sup>th</sup>, 2022****

PCO - Organising Secretariat



Organized by



[www.lung-health.org/2023](http://www.lung-health.org/2023)

# 3<sup>RD</sup> EUROPEAN BRONCHIECTASIS WORKSHOP



## Organising Committee:

Stefano Aliberti *(Italy)*

Francesco Blasi *(Italy)*

James D. Chalmers *(UK)*

MILAN - ITALY  
FEBRUARY 24<sup>th</sup>-25<sup>th</sup>, 2023

Powered by



Publi Créations

Organised by



[www.ntmbronchiectasis.org](http://www.ntmbronchiectasis.org)



# World Bronchiectasis & NTM Conference

►► HYBRID FORMAT



**PRAGUE**  
**30 JUNE - 2 JULY 2022**



EMBARC

The European Bronchiectasis Registry

Organising Secretariat



Publi Créations

[www.world-bronchiectasis-conference.org](http://www.world-bronchiectasis-conference.org)